Rui Albuquerque Carvalho

Rui Albuquerque Carvalho

Auto-generated profile, based on publicly available information

Rui Albuquerque Carvalho

Department of Life Sciences, Faculty of Science and Technology (FCTUC), University of Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2013 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
FCFilipa Carvalho
Filipa Carvalho
ABAna Burgeiro
Ana Burgeiro
RGRita Garcia
Rita Garcia
AMAntónio J. Moreno
António J. Moreno
RCRui A. Carvalho
Rui A. Carvalho
POPaulo Oliveira
Paulo Oliveira

20 July 2012 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Marco AlvesMarco Alves
Marco Alves
LRLuís Rato
Luís Rato
RCRui A. Carvalho
Rui A. Carvalho
Paula I. MoreiraPaula I. Moreira
Paula I. Moreira
Silvia SocorroSilvia Socorro
Silvia Socorro
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira

1 November 2005 in Polymer
Verified
Journal Article
Closed access
JMJoão Maia
João Maia
LFLino Ferreira
Lino Ferreira
RCRui Carvalho
Rui Carvalho
MRManuel A. Ramos
Manuel A. Ramos
MGMaria H. Gil
Maria H. Gil

9 December 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
OGO. Guryev
O. Guryev
RCR. A. Carvalho
R. A. Carvalho
SUS. Usanov
S. Usanov
AGA. Gilep
A. Gilep
RER. W. Estabrook
R. W. Estabrook
Metabolites of vitamin D 3 (D3) (cholecalciferol) are recognized as enzymatically formed chemicals in humans that can influence a wide variety of reactions that regulate a large number of cellular functions. The metabolism of D3 has been extensively studied, and a role for three different mitochondrial cytochrome P450s (CYP24A, CYP27A, and CYP27B1) has been described that catalyze the formation of the 24(OH), 25(OH), and 1(OH) metabolites of D3, respectively. The hormone 1,25-dihydroxyvitamin D 3 has been most extensively studied and is widely recognized as a regulator of calcium and phosphorous metabolism. Hydroxylated metabolites of D3 interact with the nuclear receptor and thereby influence growth, cellular differentiation, and proliferation. In this article, we describe in vitro experiments using purified mitochondrial cytochrome P450scc (CYP11A1) reconstituted with the iron-sulfer protein, adrenodoxin, and the flavoprotein, adrenodoxin reductase, and show the NADPH and time-dependent formation of two major metabolites of D3 (i.e., 20-hydroxyvitamin D 3 and 20,22-dihydroxyvitamin D 3 ) plus two unknown minor metabolites. In addition, we describe the metabolism of 7-dehydrocholesterol by CYP11A1 to a single product identified as 7-dehydropregnenolone. Although the physiological importance of these hydroxylated metabolites of D3 and their in vivo formation and mode of action remain to be determined, the rate with which they are formed by CYP11A1 in vitro suggests an important role.

1 January 2011 in Polymer
Verified
Journal Article
Closed access
JMJoão Maia
João Maia
RCRui A. Carvalho
Rui A. Carvalho
JCJorge Coelho
Jorge Coelho
PSPedro Nuno NL Simões
Pedro Nuno NL Simões
MGM. Helena Gil
M. Helena Gil

13 April 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJoão Duarte
João Duarte
PAPaula Agostinho
Paula Agostinho
RCRui A. Carvalho
Rui A. Carvalho
Rodrigo CunhaRodrigo Cunha
Rodrigo Cunha
Diabetic conditions are associated with modified brain function, namely with cognitive deficits, through largely undetermined processes. More than understanding the underlying mechanism, it is important to devise novel strategies to alleviate diabetes-induced cognitive deficits. Caffeine (a mixed antagonist of adenosine A1 and A2A receptors) emerges as a promising candidate since caffeine consumption reduces the risk of diabetes and effectively prevents memory deficits caused by different noxious stimuli. Thus, we took advantage of a novel animal model of type 2 diabetes to investigate the behavioural, neurochemical and morphological modifications present in the hippocampus and tested if caffeine consumption might prevent these changes. We used a model closely mimicking the human type 2 diabetes condition, NONcNZO10/LtJ mice, which become diabetic at 7–11 months when kept under an 11% fat diet. Caffeine (1 g/l) was applied in the drinking water from 7 months onwards. Diabetic mice displayed a decreased spontaneous alternation in the Y-maze accompanied by a decreased density of nerve terminal markers (synaptophysin, SNAP25), mainly glutamatergic (vesicular glutamate transporters), and increased astrogliosis (GFAP immunoreactivity) compared to their wild type littermates kept under the same diet. Furthermore, diabetic mice displayed up-regulated A2A receptors and down-regulated A1 receptors in the hippocampus. Caffeine consumption restored memory performance and abrogated the diabetes-induced loss of nerve terminals and astrogliosis. These results provide the first evidence that type 2 diabetic mice display a loss of nerve terminal markers and astrogliosis, which is associated with memory impairment; furthermore, caffeine consumption prevents synaptic dysfunction and astrogliosis as well as memory impairment in type 2 diabetes.